Clinical trial
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to…
NCT00348400 · Innovative Medical, Industry · Completed
Key facts
| NCT number | NCT00348400 |
|---|---|
| Title | Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost |
| Official title | Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost |
| Lead sponsor | Innovative Medical, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Glaucoma |
| Intervention type | Drug |
| Interventions | Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost |
| First posted | Jul 4, 2006 |
| Last update posted | Jun 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: